Mequon,
Wisc., March 7, 2014 –
Scientists from ENDECE Neural announced today that new pre-clinical evidence
that the company’s lead compound, NDC-1308, induces remyelination in
experimental models of MS will be presented at the 45th annual
meeting of the American Society for Neurochemistry (ASN) in Long Beach, Calif.
Wisc., March 7, 2014 –
Scientists from ENDECE Neural announced today that new pre-clinical evidence
that the company’s lead compound, NDC-1308, induces remyelination in
experimental models of MS will be presented at the 45th annual
meeting of the American Society for Neurochemistry (ASN) in Long Beach, Calif.
Title: “NDC-1308 Therapy for Inducing
Remyelination in Multiple Sclerosis Patients”
Remyelination in Multiple Sclerosis Patients”
Date: Sunday, March 9, 2014
Poster #: PS10.12
Abstract #: 10089
Authors: Steven H. Nye, Ph.D, and James G.
Yarger, Ph.D.
Yarger, Ph.D.
Location: Long Beach Convention Center,
Promenade Level 2, Grand Ballroom
Promenade Level 2, Grand Ballroom
Poster viewing time: 9:00am – 7:00pm
Author presentation: 5:30pm – 7:00pm
ENDECE Neural
recently published data showing that NDC-1308 induces a dramatic upregulation
of genes in signaling pathways involved in myelin sheath production. Here, Dr.
Nye will present new data from studies in mice showing that NDC-1308
demonstrates:
recently published data showing that NDC-1308 induces a dramatic upregulation
of genes in signaling pathways involved in myelin sheath production. Here, Dr.
Nye will present new data from studies in mice showing that NDC-1308
demonstrates:
·
Significant
remyelination in both the hippocampal and cortical brain regions using a mouse model of demyelination, in which the neurotoxicant
cuprizone was used to remove the myelin sheath from the axons (nerve fibers) of
mice
Significant
remyelination in both the hippocampal and cortical brain regions using a mouse model of demyelination, in which the neurotoxicant
cuprizone was used to remove the myelin sheath from the axons (nerve fibers) of
mice
·
Rapid
absorption into target tissues of the central nervous system (CNS)
Rapid
absorption into target tissues of the central nervous system (CNS)
·
A
favorable safety profile
A
favorable safety profile
Additionally,
the company has laid out a proposed timeline to the clinic for NDC-1308,
including plans to initiate Phase 1 clinical trials in 2015.
the company has laid out a proposed timeline to the clinic for NDC-1308,
including plans to initiate Phase 1 clinical trials in 2015.
About
NDC-1308
NDC-1308
NDC-1308 is a
novel chemical entity designed to address one of the root causes of MS, and is
being developed for potential use either alone or in combination with other MS
therapeutics that slow the progression of the disease. By controlling key genes
in pathways leading to myelin synthesis, NDC-1308 appears to induce restoration
of the lost myelin sheath that is believed to cause the devastating symptoms of
MS. NDC-1308 is a small molecule that readily crosses the blood-brain barrier,
allowing it to reach the tissues in the brain and spinal cord where promoting
myelin production is needed. NDC-1308
works by inducing differentiation of oligodendrocyte progenitor cells (OPCs)
into mature oligodendrocytes, cells that synthesize and maintain the myelin
sheath. ENDECE Neural discovered NDC-1308, and owns the intellectual property
surrounding the compound.
novel chemical entity designed to address one of the root causes of MS, and is
being developed for potential use either alone or in combination with other MS
therapeutics that slow the progression of the disease. By controlling key genes
in pathways leading to myelin synthesis, NDC-1308 appears to induce restoration
of the lost myelin sheath that is believed to cause the devastating symptoms of
MS. NDC-1308 is a small molecule that readily crosses the blood-brain barrier,
allowing it to reach the tissues in the brain and spinal cord where promoting
myelin production is needed. NDC-1308
works by inducing differentiation of oligodendrocyte progenitor cells (OPCs)
into mature oligodendrocytes, cells that synthesize and maintain the myelin
sheath. ENDECE Neural discovered NDC-1308, and owns the intellectual property
surrounding the compound.
About
ENDECE Neural
ENDECE Neural
ENDECE Neural
is a private biotechnology company at the forefront of developing therapies to
repair and potentially reverse damage caused by devastating neurological
diseases such as MS. A wholly owned subsidiary of ENDECE LLC, ENDECE Neural was
founded in 2011 to focus on the development of what could be the first drug
capable of inducing remyelination of damaged nerves in patients with MS. The
company is leveraging decades of accumulated knowledge about how activation of
estrogen receptors in a specific manner affects gene regulation. Researchers at
ENDECE Neural have identified small-molecule compounds that upregulate key
genes in pathways involved in promoting myelin sheath synthesis. ENDECE Neural
is developing NDC-1308, which appears to directly induce OPCs to differentiate
into mature oligodendrocytes that restore the depleted myelin sheath in rodent
models. ENDECE Neural discovered and owns the intellectual property
surrounding its compounds, and the company’s management team has a track record
of successfully taking products from the laboratory through FDA approval and
commercial release.
is a private biotechnology company at the forefront of developing therapies to
repair and potentially reverse damage caused by devastating neurological
diseases such as MS. A wholly owned subsidiary of ENDECE LLC, ENDECE Neural was
founded in 2011 to focus on the development of what could be the first drug
capable of inducing remyelination of damaged nerves in patients with MS. The
company is leveraging decades of accumulated knowledge about how activation of
estrogen receptors in a specific manner affects gene regulation. Researchers at
ENDECE Neural have identified small-molecule compounds that upregulate key
genes in pathways involved in promoting myelin sheath synthesis. ENDECE Neural
is developing NDC-1308, which appears to directly induce OPCs to differentiate
into mature oligodendrocytes that restore the depleted myelin sheath in rodent
models. ENDECE Neural discovered and owns the intellectual property
surrounding its compounds, and the company’s management team has a track record
of successfully taking products from the laboratory through FDA approval and
commercial release.
Tara DiMilia
Office: 908-369-7168
Mobile: 908-884-7024
……..
To comment – click the comment link shown below
…….
Share our Articles with others
…….
Share our Articles with others
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews